Brokers Set Expectations for IPSC Q3 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Investment analysts at William Blair issued their Q3 2026 earnings per share (EPS) estimates for Century Therapeutics in a research note issued on Thursday, March 20th. William Blair analyst S. Corwin expects that the company will earn ($0.47) per share for the quarter. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share.

A number of other brokerages also recently commented on IPSC. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, Piper Sandler cut their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $6.00.

Century Therapeutics Price Performance

IPSC stock opened at $0.55 on Friday. The company’s 50 day simple moving average is $0.75 and its 200-day simple moving average is $1.17. Century Therapeutics has a 52-week low of $0.52 and a 52-week high of $5.24. The firm has a market capitalization of $46.77 million, a P/E ratio of -0.30 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The company had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.67 million.

Institutional Investors Weigh In On Century Therapeutics

A number of large investors have recently added to or reduced their stakes in IPSC. Geode Capital Management LLC boosted its holdings in shares of Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock worth $1,002,000 after buying an additional 23,413 shares during the period. Jane Street Group LLC grew its position in shares of Century Therapeutics by 166.2% in the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares during the period. Marshall Wace LLP bought a new stake in Century Therapeutics during the 4th quarter valued at approximately $36,000. Finally, Barclays PLC grew its holdings in Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after buying an additional 45,797 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.